CD47 Blockade and Ischemia-Reperfusion Injury
Legacy context
The preserved Vasculox archive documents a focused research trajectory: first identifying activated CD47 as a driver of pulmonary arterial hypertension through caveolin-1 targeting, then expanding into the broader role of the thrombospondin-1-CD47 axis in vascular stress. The 2014 rat kidney transplant model study marked a pivotal step, showing that CD47 blockade reduced ischemia-reperfusion injury (IRI) and improved graft outcomes by preserving nitric oxide signaling. Modern research has built substantially on this foundation. CD47 is now recognized as a central checkpoint in IRI across multiple organ systems, including heart, liver, and brain, not just transplanted kidneys. The mechanism extends beyond nitric oxide inhibition to include regulation of macrophage phagocytosis, neutrophil infiltration, and endothelial cell survival. Recent preclinical work explores anti-CD47 antibodies and peptide antagonists as therapeutic windows to limit reperfusion injury, particularly in the context of stroke and myocardial infarction. Additionally, the interplay between CD47 and signal regulatory protein alpha (SIRPĪ±) on innate immune cells has become a key focus, suggesting that modulating this interaction could dampen sterile inflammation. While clinical translation remains early, the archived findings continue to inform current strategies aimed at protecting tissues from the damaging cascade of ischemia and reperfusion.
CD47 Blockade and Ischemia-Reperfusion Injury in Kidney Transplantation: A Review of the P
This review summarizes the scientific record concerning the use of CD47-blocking antibodies to mitigate ischemia-reperfusion injury (IRI) in the context of kidney transplantation. The focus is exclusively on animal model research and the use of delayed graft function as a research endpoint. The material presented here is for archival and educational purposes and does not constitute clinical advice or evidence of benefit in human patients.
The Biological Rationale: CD47 and Nitric Oxide Signaling
The scientific premise for this therapeutic approach rests on the role of the thrombospondin-1 (TSP1) and CD47 receptor system. According to the record, TSP1 binding to its receptor, CD47, limits nitric oxide (NO) signaling throughout the vascular system [2]. Nitric oxide is a critical regulator of cardiovascular physiology, coordinating the activities of the endothelium, the vessel wall, and circulating cells to optimize blood flow [6]. The record states that this TSP1-CD47 interaction continually opposes the action of beneficial NO in all vascular cells [4][5]. The hypothesis is that blocking this interaction with a monoclonal antibody (mAb) relieves the inhibition of NO signaling, thereby improving tissue perfusion and reducing the damage associated with IRI [2][3]. A second, distinct mechanism is also noted in the record. A particular anti-human CD47 monoclonal antibody (clone 1F7) was found to have a direct, cytotoxic effect on tumor cells in a leukemia model. This effect was described as non-apoptotic and involved a direct CD47-dependent attack on mitochondria, leading to cell death [1]. Importantly, this antibody did not kill normal leukocytes, which also express CD47, but only cells activated by transformation [1]. The record does not indicate that this direct cytotoxic mechanism is relevant to the proposed benefits in ischemia-reperfusion injury.
Preclinical Evidence in Ischemia-Reperfusion Injury Models
The evidence base for CD47 blockade in IRI is derived from animal models. The record indicates that knocking out CD47 in mice or blocking CD47 with a monoclonal antibody resulted in enhanced tissue perfusion in a number of surgical ischemia models [4][5]. Specific mention is made of substantial protection in models of liver and hindlimb IRI [4][5]. Further, treatment with anti-CD47 monoclonal antibodies was reported to dramatically improve outcomes in models of kidney, liver, brain, hindlimb, and soft tissue IRI [2]. The record details a specific experimental approach for kidney transplantation. In one Phase I grant period, researchers treated harvested rat kidneys with CD47 monoclonal antibodies prior to a period of cold storage [2]. The record states that this treatment was intended to alleviate IRI upon transplantation [2]. The record is clear that these are proof-of-concept studies in animal models, with the goal of establishing efficacy before any potential clinical development [4][5].
Delayed Graft Function as a Research Endpoint
The record explicitly connects the problem of IRI to the clinical outcomes of primary graft nonfunction and delayed graft function [2][3]. Delayed graft function is a recognized research endpoint in these preclinical studies, representing the early failure of the transplanted organ to function adequately. The record notes that IRI is responsible for delayed graft function, initial graft failure, and contributes to poor long-term graft survival [3]. The stated goal of the research is to reduce IRI to improve the success rate of standard criteria donor organs and to potentially allow greater use of expanded criteria donor (ECD) and donation after cardiac death (DCD) organs, which are more susceptible to IRI damage [2]. The record does not provide specific quantitative data on the degree to which CD47 blockade reduces the incidence of delayed graft function in these models.
Antibody Development and Characterization
The record describes the development of a panel of nine mouse monoclonal antibodies, referred to as the 400 series, which were characterized as reacting broadly across species, including human, rodent, dog, and pig [3]. This cross-species reactivity was considered a significant advantage for potential clinical development [3]. Of these, three antibodies were shown to reverse the TSP1-CD47 mediated inhibition of NO-stimulated cGMP formation in cultured cells [3]. The record indicates that one of these antibodies was to be selected for further development [3]. The record does not specify which antibody was ultimately advanced or provide comparative efficacy data among the panel.
Limitations and Gaps in the Record
The record is a collection of grant applications and project descriptions, not peer-reviewed publications of final results. As such, it provides a clear statement of hypotheses and proposed methods but is silent on several key points. The record does not provide specific numerical outcomes, such as the percentage reduction in delayed graft function or the magnitude of improvement in graft survival in the animal models. The record also does not specify the exact dosing regimens, timing of administration relative to ischemia, or the duration of follow-up in the kidney transplant models. While the record mentions the use of a rat kidney transplant model, it does not provide detailed data on renal function parameters, histology, or long-term graft outcomes from these studies. The record is also silent on the potential for adverse effects of CD47 blockade in the transplant setting, such as effects on red blood cells or other tissues that express CD47.
Conclusion
The scientific record reviewed here documents a coherent research program investigating CD47 blockade as a strategy to reduce ischemia-reperfusion injury in organ transplantation. The rationale is based on the known role of the TSP1-CD47 interaction in limiting nitric oxide signaling. Preclinical evidence from animal models of liver, hindlimb, and kidney IRI supports the hypothesis that blocking this interaction can improve outcomes. Delayed graft function is explicitly identified as a key research endpoint that this therapy aims to address. However, the record consists of research proposals and progress descriptions, and it lacks the detailed quantitative results and long-term outcome data that would be found in a completed preclinical study. The record is clear that these are preclinical findings and does not suggest they represent human clinical benefit.
This page is for educational and informational purposes only and is not medical advice. It does not solicit legal representation or evaluate claims.